[Skip to Content]
[Skip to Content Landing]
Article
April 1982

Amiodarone KeratopathyCorrelation to Dosage and Duration

Author Affiliations

From the Division of Ophthalmology, Department of Surgery, Case Western Reserve University Hospitals, Cleveland (Dr Kaplan), and Cleveland Metropolitan General Hospital (Dr Cappaert).

Arch Ophthalmol. 1982;100(4):601-602. doi:10.1001/archopht.1982.01030030603011
Abstract

• Amiodarone hydrochloride, a benzofurane derivative used for the treatment of cardiac arrhythmias, is known to cause a verticillate epithelial keratopathy, which has been classified into three stages. Patients receiving low dosages of 100 to 200 mg of amiodarone daily retain clear corneas or show stage 1 changes only, regardless of duration of treatment or total amount of substance ingested. Patients receiving higher dosages of 400 to 1,400 mg/day show stage 2 and 3 changes, depending on duration of treatment. This keratopathy progresses, even with reduced dosage; however, complete regression occurs once administration of medication is discontinued.

References
1.
Rosenbaum MB, Chiale PA, Halpern MS, et al:  Clinical efficacy of amiodarone as an antiarrhythmic agent . Am J Cardiol 1976;38:934-944.Article
2.
Cote P, Bourassa MG, Delaye J, et al:  Effects of amiodarone on cardiac and coronary hemodynamics and on myocardial metabolism in patients with coronary artery disease . Circulation 1979;59:1165-1172.Article
3.
Zakharov VN, Kuznetsov KK:  Study of the effectiveness of cordarone in different types of arrhythmia . Kardiologiia 1977;17:90-93.
4.
Jonckheer MH, Blockx P, Broeckaert I, et al:  Low T3 syndrome in patients chronically treated with an iodine containing drug, amiodarone . Clin Endocrinol 1978;9:27-35.Article
5.
Burger A, Dinichert D, Nicod P, et al:  Effect of amiodarone on serum triiodothyronine, reverse triiodothyronine, thyroxin, and thyrotropin: A drug influencing peripheral metabolism of thyroid hormones . J Clin Invest 1976;58:255-260.Article
6.
Dudognon P, Hauw JJ, DeBaecque C, et al:  Neuropathie au chlorhydrate d'amiodarone . Rev Neurol 1979;135:527-531.
7.
Meier J, Kauer B, Muller U, et al:  Neuro-myopathy during chronic amiodarone treatment . J Neurol 1979;220:231-233.Article
8.
Lambert D, Noble JP, Justrabo E, et al:  Pigmentation cutanée secondaire a l'administration d'amiodarone . Ann Dermatol Syphiligr 1975;102:277-280.
9.
Delage C, Lagac ER, Huard J:  Pseudocyanotic pigmentation of the skin induced by amiodarone: A light and electron microscopic study . Can Med Assoc J 1975;112:1205-1209.
10.
Miller HA:  Keratopathie consecutive au traitement par cordarone . Bull Soc Ophthalmol 1969;69:1059-1060.
11.
Babel J, Stangos N:  L'action de l'amiodarone sur les tissus oculaires . Schweiz Med Wochenschr 1972;102:220-222.
12.
Kaplan LJ, Cappaert WE:  Amiodarone induced corneal deposits . Invest Ophthalmol Vis Sci 1981;20( (suppl) ):85.
13.
D'Amico DJ, Kenyon KR, Ruskin JN:  Amiodarone keratopathy: Drug-induced lipid storage disease . Arch Ophthalmol 1981;99:257-261.Article
14.
Toussaint D, Pohl S:  Aspect histologique et ultrastructure des depots corneens dus au chlorhydrate d'amiodarone . Bull Soc Beige Ophtalmol 1969;153:675-686.
15.
Bockhardt H, Drenckhahn D, Lullmann-Rauch R:  Amiodarone induced lipidosis-like alterations in ocular tissues of rats . Albrecht Von Graefes Arch Klin Exp Ophthalmol 1978;207:91-94.Article
16.
Francois J:  Cornea verticillata . Bull Soc Belge Ophtalmol 1968;150:656-670.
17.
Bron AJ:  Vortex patterns of the corneal epithelium . Trans Ophthalmol Soc UK 1973;93:455-458.
18.
Bernstein HN:  Chloroquine ocular toxicity . Surv Ophthalmol 1967;12:415-446.
19.
Wilson FM, Schmitt TE, Grayson M:  Amiodarone induced cornea verticillata . Ann Ophthalmol 1980;12:657-660.
×